Parallel Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-277
| Closed | -$20K | – | 3942 |
|
|
2025
Q4 | $20K | Sell |
277
-1,276
| -82% | -$82.4K | ﹤0.01% | 2293 |
|
|
2025
Q3 | $67.7K | Sell |
1,553
-152
| -9% | -$6.14K | ﹤0.01% | 1637 |
|
|
2025
Q2 | $48.4K | Hold |
1,705
| – | – | ﹤0.01% | 1743 |
|
|
2025
Q1 | $50.3K | Buy |
1,705
+515
| +43% | +$16K | ﹤0.01% | 1627 |
|
|
2024
Q4 | $34.6K | Sell |
1,190
-187
| -14% | -$7.82K | ﹤0.01% | 1866 |
|
|
2024
Q3 | $63.2K | Buy |
1,377
+1,331
| +2,893% | +$57.8K | ﹤0.01% | 1486 |
|
|
2024
Q2 | $1.88K | Buy |
46
+29
| +171% | +$832 | ﹤0.01% | 2826 |
|
|
2024
Q1 | $434 | Hold |
17
| – | – | ﹤0.01% | 3074 |
|
|
2023
Q4 | $154 | Sell |
17
-305
| -95% | -$2.04K | ﹤0.01% | 3198 |
|
|
2023
Q3 | $2.05K | Buy |
+322
| New | +$2.77K | ﹤0.01% | 2808 |
|
|
2023
Q2 | – | Sell |
-91
| Closed | -$1.4K | – | 3495 |
|
|
2023
Q1 | $1.4K | Buy |
91
+70
| +333% | +$1.54K | ﹤0.01% | 2874 |
|
|
2022
Q4 | $466 | Sell |
21
-6
| -22% | -$89 | ﹤0.01% | 3044 |
|
|
2022
Q3 | $0 | Buy |
27
+6
| +29% | +$115 | ﹤0.01% | 3439 |
|
|
2022
Q2 | $0 | Buy |
+21
| New | +$312 | ﹤0.01% | 3298 |
|
|
2022
Q1 | – | Sell |
-171
| Closed | -$4K | – | 3227 |
|
|
2021
Q4 | $4K | Buy |
171
+161
| +1,610% | +$3.85K | ﹤0.01% | 2509 |
|
|
2021
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 3242 |
|
|
2021
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 3042 |
|
|
2021
Q1 | $0 | Buy |
+10
| New | +$245 | ﹤0.01% | 2882 |
|
Other funds holding RNAM
Parallel Advisors's RNAM Position: Q1 2026 in Review
Parallel Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 277 shares — an estimated $20K sold.
Parallel Advisors first reported a position in RNAM in Q1 2021 and held it in 18 quarters. The position peaked at $67.7K in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Parallel Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Parallel Advisors sold 277 Avidity Biosciences shares in Q1 2026, an estimated $20K.
- Parallel Advisors first reported a position in Avidity Biosciences in Q1 2021 and held it in 18 quarters.
- Parallel Advisors's Avidity Biosciences position peaked at $67.7K in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.